We can’t show the full text here under this license. Use the link below to read it at the source.
Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease
The link between obesity and asthma and the potential role of glucagon-like peptide-1 receptor drugs in metabolism and lung disease
AI simplified
Abstract
Obesity is associated with more severe asthma that is less responsive to corticosteroids.
- Obesity increases the risk of developing asthma and complicates its clinical management.
- Asthma in obese individuals can exhibit altered respiratory mechanics and immune responses.
- Glucagon-like peptide-1 receptor agonists may have anti-inflammatory and immunomodulatory effects that could benefit asthma treatment.
- Early evidence suggests these medications might improve respiratory function in obese patients with asthma.
- There is potential for a new approach to treating asthma by targeting metabolic dysfunction in patients with obesity.
AI simplified
Key numbers
1.5×
Increased Risk of Asthma
Risk of asthma in individuals with BMI ≥30 kg/m